Titan Medical Reports Voting Results From Annual and Special Meeting of Shareholders
June 10 2021 - 7:30AM
Business Wire
Welcomes Cathy Steiner as Independent
Director
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a
medical device company focused on the design and development of
surgical technologies for robotic single access surgery, today
announced the voting results from the company’s Annual and Special
Meeting of its Shareholders held on Wednesday, June 9, 2021.
All of management’s nominees for election were duly elected as
directors of the company by the shareholders presented or
represented by proxy at the meeting. A total of 56,098,112 of the
109,527,690 common shares outstanding, or 51.22%, were voted at the
meeting. The results of the vote were reported to the meeting by
Computershare, which acted as scrutineer at the meeting, as
follows:
Votes For
%
Votes Withheld
%
Paul Cataford
22,477,189
97.13
665,308
2.87
Anthony J. Giovinazzo
22,230,368
96.06
912,129
3.94
Heather L. Knight
22,375,526
96.69
766,970
3.31
David McNally
16,308,250
70.47
6,834,247
29.53
Cathy Steiner
22,462,940
97.06
679,556
2.94
Cary G. Vance
22,333,789
96.51
808,708
3.49
“I would like to take this opportunity to welcome Cathy Steiner
to our Board of Directors,” said Paul Cataford, Chairman of the
Board of Directors. “With over 20 years of experience as an
investment banker and financial and capital markets advisor for
healthcare companies, we are confident that Cathy will be a strong
contributor to the board and its committees as an independent
director. She joins Titan at a very exciting time, as we advance
our Enos™ system toward clinical studies.”
The appointment of BDO Canada LLP as independent auditors of the
company was approved by shareholders (with 52,008,750 votes for and
4,089,761 votes withheld) in respect of the motion.
Renewal of the Stock Option Plan was approved by shareholders
(with 15,852,067 votes for and 7,290,430 votes withheld) in respect
of the motion.
Approval of amendments to the Stock Option Plan for the
provision of incentive stock options was approved by shareholders
(with 15,496,101 votes for and 7,646,396 votes withheld) in respect
of the motion.
About Titan Medical Inc.
Titan Medical Inc. is a medical device company headquartered in
Toronto, Ontario and with R&D facilities in Chapel Hill, North
Carolina, is focused on enhancing robotic assisted surgery using
innovative technology through a single access point. The Enos™
robotic single access surgical system is being developed with an
ergonomic focus to provide a surgical experience that imitates
real-life movements that surgeons demand, and includes
multi-articulating instruments designed to allow surgeons an
increased range of motion in a confined space, with dexterity and
the ability to exert the forces necessary to complete common
surgical tasks. With the Enos system, Titan intends to initially
pursue gynecologic surgical indications. Certain of Titan’s robotic
assisted surgical technologies and related intellectual property
have been licensed to Medtronic plc, while retaining world-wide
rights to commercialize the technologies for use with the Enos
system.
Enos™ is a trademark of Titan Medical Inc.
For more information, visit www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws, which
reflect the current expectations of management of the Company’s
future growth, results of operations, performance, and business
prospects and opportunities. Wherever possible, words such as
“may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements, including, without limitation, references to: the
Company’s focus on the design and development of surgical
technologies for robotic single access surgery, the Enos system is
being developed with dual 3D and 2D high-definition vision systems,
multi-articulating instruments and an ergonomic surgeon
workstation, and that Titan intends to initially pursue gynecologic
surgical indications. These statements reflect management’s current
beliefs, and are based on information currently available to
management. Forward-looking statements involve significant risks,
uncertainties and assumptions. Many factors could cause the
Company’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements that may be expressed or implied by such
forward-looking statements, including, without limitation, those
listed in the “Risk Factors” section of the Company’s Annual
Information Form and Form 40-F for the fiscal year ended December
31, 2020 (which may be viewed at www.sedar.com and at www.sec.gov).
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking statements prove
incorrect, actual results, performance, or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. These factors should be
considered carefully, and prospective investors should not place
undue reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the Company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements. Except as required by law, the
Company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210610005284/en/
Kristen Galfetti Vice President, Investor Relations &
Corporate Communications +1-781-869-2553
investors@titanmedicalinc.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Sep 2023 to Sep 2024